We report the first known patient with a del(18p) and Graves disease. This deletion has previously been reported to be associated with autoimmune thyroid disease and, perhaps, with inborn errors of thyroxin biosynthesis. We present the clinical and histological information on this patient and ...
131I therapy is widely used to treat Graves' disease but may fail or course hypothyroidism. Thus, the study of prognostic factors of Graves' disease is of great clinical value. Research suggests that several factors, including the patient' s age, gender, course, serological indices, 131I ...
ConclusionsWith the aggravation of the disease, the quality of life of GO patients is getting worse and worse. The main influencing factors of the quality of life of GO patients include age, gender, diplopia, clinical active score and thyroid-stimulating hormone levels. Close attention needs to ...
If you even suspect you may have Graves’ disease, getting treatment ASAP is crucial. “While Graves’ may not seem like a serious issue at first, it can often become one later, and it definitely needs immediate medical attention either way,” says Lindsay Bischoff MD, Medical Director of t...
Application of 131I to treat Graves′ disease complicated with immune thrombocytopenia: A case report and literature review Jiang Zewen Lv Jinfu Lin Chunhao Fu Wei Authors Info & Affiliations Published: 2023 -05 -20 · DOI: 10.3760/cma.j.cn121383-20220228-02067276 22 0 0 3 1...
(defined as T3 and T4 falling below the ULN and the patient simultaneously tapering completely off their ATD). Despite benefiting from a lower starting IgG level after 12 weeks of 680mg therapy, during Weeks 13 to 24, the lower 340mg dose of batoclimab resulted in mean...
Pretibial myxoedema (PM) is a late and rare manifestation of autoimmune thyroiditis, particularly in patients with Graves' disease. It occurs in 0.5% to 4.3% of patientsdoi:10.4236/jcdsa.2015.54036Ruzhi ZhangYuhua YangWenyuan ZhuJournal of Cosmetics Dermatological Sciences & Applications...
& Tse, E. Primary immune thrombocytopenia responding to antithyroid treatment in a patient with Graves’ disease. Ann Hematol 90, 223–224 (2011). https://doi.org/10.1007/s00277-010-0983-4 Download citation Received14 April 2010 Accepted29 April 2010 Published14 May 2010 Issue DateFebruary ...
In some cases, additional testing will not be needed because a patient’s medical history and physical examination provide strong enough evidence of Graves’ disease. Although most cases of hyperthyroidism are due to Graves’ disease, an overactive thyroid gland can also be caused by other medical...
131I therapy is widely used to treat Graves' disease but may fail or course hypothyroidism. Thus, the study of prognostic factors of Graves' disease is of great clinical value. Research suggests that several factors, including the patient' s age, gender, course, serological indices, 131I ...